$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

$mrsn Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023016643 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$10.65M	$7.802M	$2.036M
YoY Change	148.69%	283.2%	18409.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.19M	$18.33M	$12.78M
YoY Change	22.86%	43.39%	77.28%
% of Gross Profit
Research & Development	$48.97M	$47.28M	$35.81M
YoY Change	18.77%	32.03%	30.61%
% of Gross Profit
Depreciation & Amortization	$324.0K	$319.0K	$205.0K
YoY Change	42.73%	55.61%	-9.29%
% of Gross Profit
Operating Expenses	$67.16M	$65.60M	$48.59M
YoY Change	19.85%	35.02%	40.33%
Operating Profit
YoY Change
Interest Expense	$1.025M	$983.0K	$724.0K
YoY Change	34.87%	35.77%	678.49%
% of Operating Profit
Other Income/Expense, Net	$2.194M	$1.638M	-$706.0K
YoY Change	-567.8%	-332.01%	771.6%
Pretax Income	-$54.31M	-$56.16M	-$47.26M
YoY Change	4.0%	18.84%	36.23%
Income Tax
% Of Pretax Income
Net Earnings	-$54.30M	-$56.20M	-$47.26M
YoY Change	4.02%	18.92%	36.22%
Net Earnings / Revenue	-509.67%	-720.33%	-2321.12%
Basic Earnings Per Share	-$0.47	-$0.52	-$0.59
Diluted Earnings Per Share	-$0.47	-$0.52	-$0.59
COMMON SHARES
Basic Shares Outstanding	114.4M shares	108.0M shares	79.93M shares
Diluted Shares Outstanding	115.6M shares	107.5M shares	79.93M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$286.6M	$273.9M	$230.1M
YoY Change	27.3%	19.07%	0.73%
Cash & Equivalents	$128.7M	$122.8M	$230.1M
Short-Term Investments	$157.9M	$151.1M
Other Short-Term Assets	$10.50M	$7.888M	$11.41M
YoY Change	-12.15%	-30.89%	226.09%
Inventory
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$297.1M	$281.8M	$241.5M
YoY Change	25.31%	16.7%	4.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.40M	$13.80M	$14.55M
YoY Change	-7.92%	-5.15%	17.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$517.0K	$588.0K	$2.247M
YoY Change	-28.59%	-73.83%	-36.16%
Total Long-Term Assets	$13.91M	$14.39M	$16.80M
YoY Change	-8.9%	-14.34%	5.25%
TOTAL ASSETS
Total Short-Term Assets	$297.1M	$281.8M	$241.5M
Total Long-Term Assets	$13.91M	$14.39M	$16.80M
Total Assets	$311.0M	$296.2M	$258.3M
YoY Change	23.24%	14.69%	4.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.92M	$18.16M	$9.775M
YoY Change	107.38%	85.74%	-16.76%
Accrued Expenses	$33.47M	$32.59M	$27.48M
YoY Change	-2.3%	18.61%	57.04%
Deferred Revenue	$20.50M	$28.77M	$16.58M
YoY Change	-21.85%	73.54%	316.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$74.92M	$83.40M	$56.46M
YoY Change	4.83%	47.71%	61.7%
LONG-TERM LIABILITIES
Long-Term Debt	$25.00M	$25.00M	$25.00M
YoY Change	0.0%	0.0%	380.77%
Other Long-Term Liabilities	$76.00K	$140.0K	$389.0K
YoY Change	-76.83%	-64.01%	22.33%
Total Long-Term Liabilities	$25.08M	$25.14M	$25.39M
YoY Change	-0.99%	-0.98%	360.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$74.92M	$83.40M	$56.46M
Total Long-Term Liabilities	$25.08M	$25.14M	$25.39M
Total Liabilities	$221.2M	$231.9M	$117.7M
YoY Change	86.96%	96.96%	135.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$765.2M	-$710.9M	-$497.7M
YoY Change	39.13%	42.84%	57.94%
Common Stock	$855.0M	$775.1M	$638.3M
YoY Change	24.98%	21.44%	24.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$89.80M	$64.29M	$140.5M
YoY Change
Total Liabilities & Shareholders Equity	$311.0M	$296.2M	$258.3M
YoY Change	23.24%	14.69%	4.18%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$54.30M	-$56.20M	-$47.26M
YoY Change	4.02%	18.92%	36.22%
Depreciation, Depletion And Amortization	$324.0K	$319.0K	$205.0K
YoY Change	42.73%	55.61%	-9.29%
Cash From Operating Activities	-$61.83M	-$29.01M	-$7.955M
YoY Change	38.1%	264.61%	-70.56%
INVESTING ACTIVITIES
Capital Expenditures	$399.0K	$911.0K	$329.0K
YoY Change	-160.73%	176.9%	188.6%
Acquisitions
YoY Change
Other Investing Activities	-$5.040M	$2.307M
YoY Change	-94.39%
Cash From Investing Activities	-$5.439M	$1.396M	-$329.0K
YoY Change	-93.99%	-524.32%	188.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	73.18M	$21.55M	$60.39M
YoY Change	80.57%	-64.32%	12695.34%
NET CHANGE
Cash From Operating Activities	-61.83M	-$29.01M	-$7.955M
Cash From Investing Activities	-5.439M	$1.396M	-$329.0K
Cash From Financing Activities	73.18M	$21.55M	$60.39M
Net Change In Cash	5.907M	-$6.060M	$52.11M
YoY Change	-106.24%	-111.63%	-295.43%
FREE CASH FLOW
Cash From Operating Activities	-$61.83M	-$29.01M	-$7.955M
Capital Expenditures	$399.0K	$911.0K	$329.0K
Free Cash Flow	-$62.23M	-$29.92M	-$8.284M
YoY Change	41.06%	261.13%	-69.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001442836
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38129
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Mersana Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3562403
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	840 Memorial Drive
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	498-0020
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	MRSN
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	114385810	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122825000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128885000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151094000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151827000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30000000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7888000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8507000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	281807000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	319219000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3994000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3985000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9806000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10475000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	588000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	661000	usd
CY2023Q1	us-gaap	Assets Assets	296195000	usd
CY2022Q4	us-gaap	Assets Assets	334340000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	18156000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13951000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32588000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43184000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28769000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	30610000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2904000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2798000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	985000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	990000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	83402000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	91533000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7773000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8575000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	25004000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	24929000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	115582000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	117043000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	140000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	203000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	231901000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	242283000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	109061074	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	109061074	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105144864	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105144864	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	775125000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	746889000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-152000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-710854000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-654691000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	64294000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	92057000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	296195000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	334340000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7802000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2036000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47275000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35806000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18328000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12782000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	65603000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	48588000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2621000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	983000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	724000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1638000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-706000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56163000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	164000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55999000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47258000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-56163000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-56163000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-47258000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47258000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107514655	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107514655	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79928591	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79928591	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	121741000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60462000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5485000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47258000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	140526000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	92057000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21795000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6407000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	164000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56163000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	64294000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-56163000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-47258000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	319000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	205000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1411000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6407000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5485000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-152000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-194000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-620000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4728000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2524000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10327000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2159000	usd
CY2023Q1	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	669000	usd
CY2022Q1	mrsn	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	889000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-697000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-579000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3302000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	38254000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29005000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7955000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	66000000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	63693000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	911000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	329000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1396000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-329000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21730000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60374000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	34000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	76000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21549000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60394000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6060000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52110000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123303000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	230535000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	169000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	457000	usd
CY2023Q1	mrsn	Equity Issuance Costs Incurred During Noncash Or Part Noncash Transaction EquityIssuanceCostsIncurredDuringNoncashOrPartNoncashTransaction	66000	usd
CY2022Q1	mrsn	Equity Issuance Costs Incurred During Noncash Or Part Noncash Transaction EquityIssuanceCostsIncurredDuringNoncashOrPartNoncashTransaction	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	791000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	531000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56200000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47300000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-710900000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of Credit Risk and Off-balance Sheet RiskFinancial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	147653000	usd
CY2023Q1	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	0	usd
CY2023Q1	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	3302000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	144351000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3944000	usd
CY2022Q1	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	40000000	usd
CY2022Q1	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	1746000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	42198000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5110000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	11000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128885000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122825000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	177947000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	230057000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123303000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	178425000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	230535000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	151085000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	63000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	54000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151094000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	151980000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	31000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	184000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	151827000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	7	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42400000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	13414000	usd
CY2022Q4	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	14822000	usd
CY2023Q1	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	7801000	usd
CY2022Q4	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	11536000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4754000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11558000	usd
CY2023Q1	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	3488000	usd
CY2022Q4	mrsn	Accrued Preclinical Expenses Current AccruedPreclinicalExpensesCurrent	2767000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2726000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1865000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	405000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	636000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32588000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43184000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25000000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	302000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	306000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	25004000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013	mrsn	Class Of Warrant Or Right Securities Called By Warrants Or Rights Number Issued ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued	129491	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.05
CY2013	mrsn	Contractual Life Of Warrants ContractualLifeOfWarrants	P10Y
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	22590	shares
CY2023Q1	mrsn	Warrants Exercised In Period WarrantsExercisedInPeriod	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15769504	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15769504	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11944664	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10051283	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.84
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2530740	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.07
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8826	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.80
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	273670	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.08
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12299527	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.07
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5902352	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.51
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.06
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.39
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6407000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5485000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6407000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5485000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y25D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15769504	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11524655	shares

Files In Submission

Name	View Source	Status
mrsn-20230331_cal.xml	Edgar Link	unprocessable
mrsn-20230331_lab.xml	Edgar Link	unprocessable
0001628280-23-016643-index-headers.html	Edgar Link	pending
0001628280-23-016643-index.html	Edgar Link	pending
0001628280-23-016643.txt	Edgar Link	pending
0001628280-23-016643-xbrl.zip	Edgar Link	pending
exhibit101oxford-svbxmersa.htm	Edgar Link	pending
exhibit102merck2014license.htm	Edgar Link	pending
exhibit103merck2014amendme.htm	Edgar Link	pending
exhibit104merck2014amendme.htm	Edgar Link	pending
exhibit105merck2014amendme.htm	Edgar Link	pending
exhibit1062015receptalicen.htm	Edgar Link	pending
exhibit1072015receptalicra.htm	Edgar Link	pending
exhibit31110-qfy2023q1.htm	Edgar Link	pending
exhibit31210-qfy2023q1.htm	Edgar Link	pending
exhibit32110-qfy2023q1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsn-20230331.htm	Edgar Link	pending
mrsn-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mrsn-20230331_def.xml	Edgar Link	unprocessable
mrsn-20230331_pre.xml	Edgar Link	unprocessable
mrsn-20230331_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

2023 Q2 Form 10-Q Financial Statement

#000162828023016643 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN Mersana Therapeutics, Inc. Stock $mrsn

2023 Q2 Form 10-Q Financial Statement

#000162828023016643 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn